China CAS:84371-65-3 Manufacturer

Our growth depends within the innovative equipment, fantastic talents and repeatedly strengthened technology forces for CAS:84371-65-3, Our experienced specialized workforce will probably be wholeheartedly at your provider. We sincerely welcome you to check out our web-site and organization and mail us your inquiry.
CAS:84371-65-3, We've got more than 200 staff including experienced managers, creative designers, sophisticated engineers and skilled workers. Through hard work of all employees for the past 20 years own company grew stronger and stronger. We always apply the "client first" principle. We also always fulfill all contracts to the point and therefore enjoy excellent reputation and trust among our customers. You are very welcome to personally visit our company.We hope to start a business partnership on the basis of mutual benefit and successful development . For more information make sure you do no hesitate to contact us.

Hot Products

  • Progesterone

    Progesterone

    Progesterone has EP, USP, CP, JP, IP and KP specifications. CEP available, EU-GMP,FDA approved.

    CAS:57-83-0

  • Ganciclovir

    Ganciclovir

    Ganciclovir has CP ,EP, USP specification. DMF and GMP approved.

    CAS:82410-32-0

  • Cbz-Valganciclovir

    Cbz-Valganciclovir

    Cbz-Valganciclovir,N-Carbobenzyloxy-L-valinyl-ganciclovir (cas# 194154-40-0) is a compound useful in organic synthesis.

    CAS:194154-40-0

  • Mifepristone Tablets

    Mifepristone Tablets

    Mifepristone Tablets Specifications:10mg*1
    Indications:Emergency Contraceptive
  • Misoprostol Tablets 0.2mg*3

    Misoprostol Tablets 0.2mg*3

    Misoprostol Tablets 0.2mg*3
    Specifications:0.2mg*3
    Indications:Abortion
  • 3-Oxo-4-androsten-17β-carboxylic acid

    3-Oxo-4-androsten-17β-carboxylic acid

    3-Oxo-4-androsten-17β-carboxylic acid is an intermediate of Dutasteride.

    CAS:302-97-6

Send Inquiry

X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept